Inventages

Inventages Venture Capital, founded in 2000 by Gunnar Weikert, is the venture capital arm of Nestlé, headquartered in Nassau, Bahamas. The firm specializes in health care, life sciences, pharmaceuticals, cosmeceuticals, enabling technologies, and medical devices. Inventages has a broad investment focus, participating in seed, early, mid, and late-stage ventures. Notable investments include Accera, a biotechnology firm focused on therapies for neurodegenerative diseases, and Phagenesis, which develops treatments for dysphagia. Other significant investments are Shield Therapeutics, known for its iron deficiency treatments, and Cognoptix, which is developing diagnostics for Alzheimer's disease​. Inventages typically invests with an average round size of $14 million, demonstrating a strong commitment to substantial funding rounds. The firm is actively involved in guiding its portfolio companies through strategic growth and development stages. Key team members include Gunnar Weikert (Founder and CEO), Thomas Bayerl, and Wolfgang Reichenberger, all bringing significant expertise in venture capital and life sciences to the table. Inventages is particularly noted for its rigorous due diligence process and a strong focus on the commercial viability of scientific innovations. This approach has enabled them to support groundbreaking developments in health and wellness sectors​.